Complete FDA and NHTSA recall records dated in April 2020.
These records include useful source details for the selected month.
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.
